Veraxa Biotech (NASDAQ: VRXA) has expanded its laboratory footprint at its existing research and development site in Heidelberg, Germany, under a previously executed long-term lease agreement. The expansion will support planned growth of the company’s R&D team, installation of new laboratory equipment, and completion of infrastructure needed to advance future development activities. This move aligns with Veraxa's efforts to advance its growing portfolio of proprietary and partnered oncology programs from discovery-stage research toward early clinical development.
The company’s pipeline is centered on its BiTAC platform, which includes BiTAC-TCE and BiTAC-ADC candidates. These therapies are designed to enable tumor-restricted activation of cancer therapies through the use of complementary precursor molecules, potentially reducing off-target effects and improving safety profiles. Veraxa's expansion in Heidelberg, a prominent European biotech hub, positions the company to leverage local talent and infrastructure to accelerate its drug development pipeline.
The additional space will accommodate new hires and the installation of advanced laboratory equipment, which are critical for advancing the BiTAC platform. Veraxa's pipeline includes a range of antibody-based therapeutics, such as bispecific T cell engagers and bispecific ADCs, built on transformative technologies and quality-by-design principles. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research.
This expansion comes as Veraxa progresses its programs toward clinical milestones. The company's focus on tumor-restricted activation could address key challenges in oncology, such as minimizing damage to healthy tissues while maximizing therapeutic efficacy. The Heidelberg site is expected to play a central role in advancing these candidates through preclinical and early clinical stages.
For more details, the full press release is available at https://ibn.fm/n3t6U. Updates and news related to Veraxa can be found in the company’s newsroom at https://ibn.fm/VRXA.
